Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190003 | 0.91 | MAPK1 (0.47) | CYP11B2MAPK1BCHECYP19A1ACHE | |
| SCHEMBL2817700 | 0.79 | CYP11B2 (0.43) | CYP11B2MAPK1CYP19A1ALDH1A1 | |
| SCHEMBL9493247 | 0.79 | CYP11B2 (0.43) | CYP11B2MAPK1CYP19A1ALDH1A1 | |
| SCHEMBL9493435 | 0.79 | CYP11B2 (0.43) | CYP11B2MAPK1CYP19A1ALDH1A1 | |
| SCHEMBL9493929 | 0.78 | IDO1 (0.42) | CYP11B2MAPK1 | |
| SCHEMBL13486050 | 0.78 | CYP11B2 (0.53) | CYP11B2MAPK1BCHECYP19A1CYP11B1 | |
| SCHEMBL11401439 | 0.76 | ALDH1A1 (0.42) | CYP11B2MAPK1CYP11B1ALDH1A1 | |
| SCHEMBL3188605 | 0.75 | MAPK1 (0.44) | CYP11B2MAPK1MTNR1ACYP11B1ALDH1A1 | |
| SCHEMBL3493755 | 0.74 | CYP11B2 (0.50) | CYP11B2MTNR1AMTNR1BOPRL1GRIN2B | |
| SCHEMBL3201410 | 0.73 | KDM4A (0.42) | CYP11B2MTNR1AMTNR1BOPRL1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041722-A1 | ORGANIC COMPOUNDS | HU QI-YING | 2010-02-18 | — | — | US | disclosed |
| US-20100041722-A1 | ORGANIC COMPOUNDS | HU QI-YING | 2010-02-18 | — | — | US | disclosed |
| US-20100041722-A1 | ORGANIC COMPOUNDS | HU QI-YING | 2010-02-18 | — | — | US | disclosed |
| EP-2094669-A2 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008076862-A2 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076862-A2 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041722-A1 | ORGANIC COMPOUNDS | CYP11B1, CYP11B2, CYP21A2 | CYP11B2 2/4885MAPK1 1447/4885MTNR1A 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.